Table 5.
Second MRI evaluation. Nine patients were eligible for a second MRI evaluation in frame of the follow-up study. The MRI was run after 17 ± 2 months from the first MRI re-evaluation and next generation sequencing (NGS) analysis. In 7 patients no new lesions were discovered, while in two patients (ID 92381 and 92502) new HCC lesions were found, which had been undetectable at the time of the variant analysis.
| Patient’s ID | Variants | Second MRI Re-Evaluation |
|---|---|---|
| 92379 | none | no new lesion |
| 92381 | BAX | Early HCC (confirmed) HCC (newly discovered) |
| 92382 | AC055811.2; FLCN | no new lesion |
| 92389 | none | no new lesion |
| 92396 | HNF1A | HGDN (confirmed) |
| 92397 | HNF1A | no new lesion |
| 92500 | CYP2B6; WRN | no new lesion |
| 92502 | BRAF; NBN; PTEN | HCC (confirmed) HCC (newly discovered) |
| 92504 | ASXL1 | no new lesion |